Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
China ARCHES: Enzalutamide + ADT in mHSPC
NCT04076059Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of enzalutamide in prostate cancer (PCa) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Time to Prostrate Specific Antigen Progression at 38 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04076059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04076059.